Ocrelizumab lowers risk of upper limb disability progression

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.

Ocrelizumab lowers risk of upper limb disability progression

Postby MSUK » Fri Oct 27, 2017 7:06 am

Ocrelizumab lowers risk of upper limb disability progression in PPMS patients #ECTRIMS

Upper limb (UL) function impairment is prevalent among patients with primary progressive multiple sclerosis (PPMS) and alters a patient’s quality of life. Researchers set out to evaluate the effect of Ocrelizumab on upper limb function using the nine-hole peg test (9HPT)...Read more - http://www.ms-uk.org/ocrelizumab-lowers-risk-upper-limb-disability-progression-ppms-patients-ectrims

Image
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2876
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Ocrevus (Ocrelizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service